Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and substantial weight reduction compared to single-agonist therapies and placebo.
If you have Type 2 Diabetes or Obesity, Tirzepatide is a highly effective once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1) to lower blood sugar and promote significant weight loss. It is generally considered superior to older single-agonist drugs. To use it safely, you must start with a low dose and gradually increase it to minimize stomach issues, while maintaining a healthy diet and exercise routine. Access may be limited by cost and insurance coverage, so discuss financial assistance or insurance prior authorization with your doctor.
The synergistic effects derived from the dual GIP and GLP-1 agonism result in a more robust reduction in HbA1c and body weight compared to single-agonist agents.
Why this rating
Based on Phase 3 RCTs (SURPASS, SURMOUNT) and real-world evidence.
Source
Tirzepatide in Egypt: A New Era in Type 2 Diabetes and Obesity Management
Hossam Arafa Ghazi · 2026
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →